Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Receivables (2018 - 2022)

Ironwood Pharmaceuticals (IRWD) has disclosed Non-Current Receivables for 5 consecutive years, with $14.6 million as the latest value for Q4 2022.

  • Quarterly Non-Current Receivables fell 39.21% to $14.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $14.6 million through Dec 2022, down 39.21% year-over-year, with the annual reading at $14.6 million for FY2022, 39.21% down from the prior year.
  • Non-Current Receivables hit $14.6 million in Q4 2022 for Ironwood Pharmaceuticals, up from $14.4 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $32.6 million in Q4 2019 to a low of $14.1 million in Q1 2022.
  • Historically, Non-Current Receivables has averaged $22.1 million across 5 years, with a median of $23.2 million in 2020.
  • Biggest five-year swings in Non-Current Receivables: soared 55.22% in 2019 and later crashed 39.98% in 2022.
  • Year by year, Non-Current Receivables stood at $21.0 million in 2018, then skyrocketed by 55.22% to $32.6 million in 2019, then decreased by 28.21% to $23.4 million in 2020, then grew by 2.55% to $24.0 million in 2021, then plummeted by 39.21% to $14.6 million in 2022.
  • Business Quant data shows Non-Current Receivables for IRWD at $14.6 million in Q4 2022, $14.4 million in Q3 2022, and $14.3 million in Q2 2022.